Journal of
eISSN: 2376-0060
Submit manuscript...
Mini Review Volume 13 Issue 2
Dual phosphodiesterase 3 and 4 inhibition in chronic obstructive pulmonary disease: mechanistic rationale and clinical translation of Ensifentrine
Prakhar Anand, Mark Georgy, Yashi Ballal, Mahtab Nezafat, Raghav Gupta
Received: June 17, 2026 | Published: June 24, 2026
Citation: Anand P, Georgy M, Ballal Y, et al. Dual phosphodiesterase 3 and 4 inhibition in chronic obstructive pulmonary disease: mechanistic rationale and clinical translation of Ensifentrine. J Lung Pulm Respir Res. 2026;13(2):34-38. DOI: 10.15406/jlprr.2026.13.00342
Abstract
Chronic obstructive pulmonary disease (COPD) remains a leading cause of morbidity, mortality, and healthcare utilization globally, despite the widespread adoption of dual bronchodilator and triple inhaled corticosteroid–containing regimens. A substantial proportion of patients continue to experience persistent dyspnea, impaired health status, and recurrent exacerbations, underscoring significant therapeutic gaps in current management paradigms. Targeting both bronchomotor tone and airway inflammation through complementary mechanisms represents a rational strategy to improve clinical outcomes. Phosphodiesterase (PDE) enzymes regulate intracellular cyclic adenosine monophosphate (cAMP), a central mediator of airway smooth muscle relaxation and inflammatory signaling. While selective PDE4 inhibition, exemplified by roflumilast, reduces exacerbation risk in selected COPD phenotypes, its systemic adverse effects have limited its routine clinical utility. Dual inhibition of PDE3 and PDE4 via inhaled delivery offers the potential to combine bronchodilation and anti-inflammatory activity while minimizing systemic exposure. Ensifentrine, a first-in-class inhaled dual PDE3/4 inhibitor, has demonstrated clinically meaningful improvements in lung function, respiratory symptoms, and exacerbation outcomes with a favorable safety profile in the pivotal Phase 3 ENHANCE trials. This mini-review synthesizes the mechanistic rationale for dual PDE inhibition, evaluates available clinical evidence, and discusses its potential positioning within contemporary COPD management. We also highlight limitations of current data and future research priorities. Dual PDE inhibition represents a biologically coherent and clinically promising strategy that may expand therapeutic options for patients with persistent symptom burden and exacerbation risk despite optimized inhaled therapy.
Keywords: chronic obstructive pulmonary disease, ensifentrine, phosphodiesterase 3/4 inhibition, exacerbations, bronchodilation, airway inflammation
©2026 Anand, et al. This is an open access article distributed under the terms of the, which permits unrestricted use, distribution, and build upon your work non-commercially.